Dextech Medical (DEX.SL) Stock Price

Dextech Medical Price

CLOSED
9.48
​
Market closed

Dextech Medical stock price

Access this data via the Eulerpool API

Dextech Medical business model & stock analysis

Dextech Medical AB engages in the provision of research and development of drug candidates for urological oncology. The company is headquartered in Uppsala, Uppsala and currently employs 1 full-time employees. The company went IPO on 2014-06-19. The company is focused on prostate cancer, but also other cancers and non-malignant diseases. The company develops drug canditates based on modified carbohydrate molecule combined with active substances. The firm has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes: OsteoDex, for treatment of bone metastases in castration resistant prostate cancer (CRPC); SomaDex, based on endogenous hormone, somatostatin, and aimed at treatment of acromegaly, neuroendocrine tumors and palliative treatment of CRPC; and CatDex, for instillation treatment of bladder cancer.

Frequently asked questions about Dextech Medical

Converted at the current exchange rate, the Dextech Medical share trades at 0.84 EUR (9.48 SEK).

The revenue cannot currently be calculated for Dextech Medical.

The profit of Dextech Medical is -6.46 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Dextech Medical is currently -27.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dextech Medical stock.

The P/S cannot be calculated for Dextech Medical currently.

The Eulerpool Quality Score for Dextech Medical is 2/10.

The ISIN of Dextech Medical is SE0005881489. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Dextech Medical is DEX.SL. The ticker symbol is used to trade Dextech Medical shares on the stock exchange.

Fair ValueTerminal
8.72 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Jun 19, 2014
ISIN
SE0005881489
Cusip
W2378Y100
Market capitalization
175.29 M SEKMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
9.58
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-35.29 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-0.35 SEK
Net Debt / EBIT
—
Debt/Equity
0.00
Last updated Sep 29, 2026, 6:02 PM

Dextech Medical Peer Group